Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply

被引：0
作者：
Ellis, Matthew J. [1 ]
Robertson, John F. R. [2 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Nottingham, Derby, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 16期
关键词：
FULVESTRANT; 500; MG; ANASTROZOLE; TRIAL; 1ST;
D O I：
10.1200/JCO.2016.66.6727
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1960 / +
页数：3
相关论文
共 8 条
[1]   Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].
Bachelot, Thomas ;
Bourgier, Celine ;
Cropet, Claire ;
Ray-Coquard, Isabelle ;
Ferrero, Jean-Marc ;
Freyer, Gilles ;
Abadie-Lacourtoisie, Sophie ;
Eymard, Jean-Christophe ;
Debled, Marc ;
Spaeth, Dominique ;
Legouffe, Eric ;
Allouache, Djelila ;
El Kouri, Claude ;
Pujade-Lauraine, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724
[2]   Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].
Baselga, Jose ;
Campone, Mario ;
Piccart, Martine ;
Burris, Howard A., III ;
Rugo, Hope S. ;
Sahmoud, Tarek ;
Noguchi, Shinzaburo ;
Gnant, Michael ;
Pritchard, Kathleen I. ;
Lebrun, Fabienne ;
Beck, J. Thaddeus ;
Ito, Yoshinori ;
Yardley, Denise ;
Deleu, Ines ;
Perez, Alejandra ;
Bachelot, Thomas ;
Vittori, Luc ;
Xu, Zhiying ;
Mukhopadhyay, Pabak ;
Lebwohl, David ;
Hortobagyi, Gabriel N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529
[3]   Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer [J].
Di Leo, Angelo ;
Jerusalem, Guy ;
Petruzelka, Lubos ;
Torres, Roberto ;
Bondarenko, Igor N. ;
Khasanov, Rustem ;
Verhoeven, Didier ;
Pedrini, Jose L. ;
Smirnova, Iya ;
Lichinitser, Mikhail R. ;
Pendergrass, Kelly ;
Garnett, Sally ;
Lindemann, Justin P. O. ;
Sapunar, Francisco ;
Martin, Miguel .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4594-4600
[4]   Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study [J].
Ellis, Matthew J. ;
Llombart-Cussac, Antonio ;
Feltl, David ;
Dewar, John A. ;
Jasiowka, Marek ;
Hewson, Nicola ;
Rukazenkov, Yuri ;
Robertson, John F. R. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) :3781-+
[5]  
Reinert T, 2016, J CLIN ONCOL, V34, P1959
[6]   Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study [J].
Robertson, John F. R. ;
Lindemann, Justin P. O. ;
Llombart-Cussac, Antonio ;
Rolski, Janusz ;
Feltl, David ;
Dewar, John ;
Emerson, Laura ;
Dean, Andrew ;
Ellis, Matthew J. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) :503-511
[7]   Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study [J].
Robertson, John F. R. ;
Llombart-Cussac, Antonio ;
Rolski, Janusz ;
Feltl, David ;
Dewar, John ;
Macpherson, Euan ;
Lindemann, Justin ;
Ellis, Matthew J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4530-4535
[8]   Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer [J].
Turner, Nicholas C. ;
Ro, Jungsil ;
Andre, Fabrice ;
Loi, Sherene ;
Verma, Sunil ;
Iwata, Hiroji ;
Harbeck, Nadia ;
Loibl, Sibylle ;
Bartlett, Cynthia Huang ;
Zhang, Ke ;
Giorgetti, Carla ;
Randolph, Sophia ;
Koehler, Maria ;
Cristofanilli, Massimo .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) :209-219
1